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Abstract
 
Unlike naive T cells, effector T cells can be activated by either T cell receptor signal or costim-
ulatory signal alone and therefore the absence of costimulatory molecules on tissue cells cannot
explain the tolerance mechanism at the effector phase. Here we report that PD-L1, the ligand
for the immunoinhibitory receptor PD-1, was expressed on vascular endothelium in peripheral
tissues. Liver nonparenchymal cells including sinusoidal endothelial cells and Kupffer cells
constitutively expressed PD-L1 and inhibited proliferation and cell division of activated T
cells expressing PD-1. The absence of PD-1 induced proliferation of effector T cells in the
adenovirus-infected liver and resulted in rapid clearance of the virus. These results indicate that
PD-1 plays an important role in T cell tolerance at the effector phase and the blockade of the
PD-1 pathway can augment antiviral immunity.
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Introduction
 
It is well established that activation of naive T cells requires
both TCR signal and costimulatory signal (1). When naive
T cells differentiate into effector cells, they change their
activation requirement. Effector T cells are much less de-
pendent on costimulation than naive T cells. Effector T
cells, unlike naive T cells, can be activated by TCR signal
alone (2, 3). A more perplexing and less easily understand-
able observation is that effector T cells can be activated by
costimulatory signal in the absence of TCR signal (4, 5). As
effector T cells can be easily activated, their negative regu-
latory system should play vital roles in the maintenance of
peripheral tolerance. Nevertheless, little is known about
the mechanism that prevents undesirable or excessive acti-
vation of effector T cells in the periphery.
PD-1, a member of the CD28 family, is a negative regu-
lator of the immune system (6–8). PD-1 is induced on T
cells, B cells, and myeloid cells upon activation in vitro (9),
but predominantly expressed on activated T cells in vivo
(10). PD-1 has two tyrosine residues in its cytoplasmic re-
gion; the NH
 
2
 
-terminal and COOH-terminal residues are
located in the immunoreceptor tyrosine-based inhibitory
motif (ITIM) and the immunoreceptor tyrosine-based
switch motif (ITSM), respectively (11). Cross-linking of
PD-1 with antigen receptor induces phosphorylation of the
ITSM tyrosine and recruits SHP-2 to deliver a negative
signal (12). PD-1 is expressed on double negative thy-
mocytes and appears to modulate positive selection in thy-
mus (13). PD-1–deficient (PD-1
 
 
 
/
 
 
 
) mice crossed with
H-2L
 
d
 
–specific 2C-TCR transgenic mice on the H-2
 
b/d
 
background develop chronic and systemic graft-versus-
host–like disease, although the majority of 2C-expressing
cells are deleted in thymus (14). PD-1 deficiency causes
organ-specific autoimmune diseases depending on genetic
backgrounds. C57BL/6-PD-1
 
 
 
/
 
 
 
 mice develop lupus-
like arthritis and glomerulonephritis (14), while BALB/c-
PD-1
 
 
 
/
 
 
 
 mice suffer from fatal dilated cardiomyopathy
with IgG deposition in heart (15). These results indicate
that PD-1 may be involved in peripheral tolerance as well
as central tolerance.
Recently PD-L1 (B7-H1) and PD-L2 (B7-DC) were
identified as ligands for PD-1 (16–19). mRNA for PD-L1
is constitutively expressed in nonlymphoid tissues such as
heart, lung, placenta, kidney, and liver (16, 17). Eppihimer
et al. suggested that the source of PD-L1 mRNA in pe-
ripheral tissues might be vascular endothelium (20). Hu-
man PD-L2 mRNA is expressed in nonlymphoid tissues as
well as human PD-L1, while murine PD-L2 mRNA ex-
pression is weaker and more restricted than that of murine
PD-L1 (18, 21). Cell surface PD-L1 expression is broadly
induced on APCs such as DCs, macrophages, and B cells,
whereas surface PD-L2 is selectively expressed on DCs and
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some macrophages after stimulation (22, 23). In addition,
PD-L1 is expressed on the surface of hematopoietic and
nonhematopoietic tumor cells, while surface PD-L2 ex-
pression has not been reported on nonhematopoietic cells
(22, 23). The distinct expression of PD-L1 and PD-L2 sug-
gests that PD-L1 may function as the major ligand for PD-1
at least in the murine immune system.
Interestingly, PD-1 ligands (PD-Ls) show different tissue
distributions from those of the other B7 molecules, in spite
of their structural similarity. In contrast to constitutive ex-
pression of PD-Ls in peripheral tissues, B7–1 and B7–2
expression is restricted to lymphoid organs, primarily on
APCs (1, 24), suggesting that they may exhibit distinct
functions at different phases of immune responses. PD-1
expression on activated T cells and constitutive expression
of PD-L1 in peripheral tissues led to the hypothesis that
PD-1/PD-L1 interaction might occur at the effector phase
of immune responses when activated T cells migrate into
sites of inflammation or infection.
It has been known that the liver often induces peripheral
tolerance rather than immunity (25, 26). Allogenic liver
transplantation across incompatible MHC barriers is often
successful without the need for immunosuppression (27).
In addition, administration of antigen via portal vein effi-
ciently induces antigen-specific tolerance (28). Further-
more, immune responses against hepatitis viruses such as
HBV and HCV are commonly ineffective and result in
chronic persistence of viral infection. Liver nonparenchy-
mal cells (LNPCs)
 
*
 
 including Kupffer cells and liver sinu-
soidal endothelial cells (LSECs) constitutively expressed a
series of cell-surface molecules associated with antigen pre-
sentation, such as MHC class I and II, ICAM-1 (CD54),
B7–1, and B7–2, suggesting their involvement in the im-
mune response (26, 29–31). Recent studies suggest that
LNPCs such as LSECs and Kupffer cells may be involved
in the hepatic tolerance induction (26, 29, 32), but its mo-
lecular mechanism remains unknown.
We found that PD-L1 was constitutively expressed on
LNPCs. The regulatory function of PD-1 at the effector
phase of immune responses in the liver was analyzed using
an in vitro culture system and an in vivo liver injury
model induced by adenovirus infection. Here, we report
that constitutive expression of PD-L1 on LNPCs is essen-
tial to inhibit proliferation of activated T cells in the liver,
suggesting that the PD-1/PD-L1 system may play impor-
tant roles in negative regulation of immune responses in
the liver.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6) mice were purchased from Japan SLC.
PD-1
 
 
 
/
 
 
 
 mice (33) were backcrossed to B6 mice for 11 genera-
tions. The animals were maintained under specific pathogen-free
conditions.
 
Adenovirus Infection.
 
Type 5 adenovirus with deletions in the
E1 and E3 regions and carrying the 
 
lacZ
 
 gene (Ad-lacZ) was
propagated in 293 cells and purified on cesium chloride gradient
as described previously (34). Mice were intravenously injected
with 10
 
9
 
–10
 
10
 
 PFU of Ad-lacZ.
 
Isolation of Heart Endothelial Cells.
 
Endothelial cells (ECs)
were isolated from hearts as described (35) with some modifica-
tions. Briefly, heart tissue was digested with collagenase. Cells
were preincubated with murine Ig to block Fc receptors and in-
cubated with FITC-conjugated anti-CD31, CD105, and isolec-
tin B4, followed by anti-FITC microbeads. ECs were purified by
positive selection with magnetic-activated cell-sorting (MACS)
separation columns (Miltenyi Biotec).
 
Isolation of LNPCs.
 
LNPCs were isolated using the pronase E
method as described previously (36) with some modifications.
Briefly, the liver was perfused and incubated with pronase E
(Merck) solution. LNPCs were separated by density gradient cen-
trifugation. The relative distribution of Kupffer cells (CD54
 
 
 
,
CD11b
 
high
 
) and LSECs (CD54
 
 
 
, CD11b
 
low
 
) in the cell suspen-
sion was 20–25% and 75–80%, respectively.
 
Isolation of Kupffer Cells and LSECs.
 
Kupffer cells and LSECs
were purified from LNPCs using MACS. Briefly, LNPCs were
preincubated with murine Ig to block Fc receptors and incubated
with anti-CD11b microbeads. Kupffer cells and LSECs were pu-
rified by positive and negative selection with MACS separation
columns, respectively.
 
Isolation of Intrahepatic Lymphocytes.
 
Intrahepatic lymphocytes
(IHLs) were isolated from livers as described previously (37).
Briefly, liver tissue was passed through a 200-gause stainless steel
mesh and mononuclear cells were purified by Percoll gradient
centrifugation. RBCs contained in the mononuclear cell prepara-
tion were lysed by ammonium chloride.
 
Activation of T Cells.
 
Naive T cells (
 
 
 
90% purity) were pu-
rified from spleens and lymph nodes by negative selection using
T cell enrichment column (Genzyme). Naive T cells (3 
 
 
 
 10
 
5
 
cells/well) were incubated on anti-CD3 mAb (2C11, 10 
 
 
 
g/
ml) coated 96-well flat-bottomed plates for 48 h. Proliferation
was determined by labeling of cultures for the last 6 h with
BrdU using Proliferation ELISA kit (Roche). For cytokine as-
says, culture supernatants were harvested at 48 h after activation.
IFN-
 
 
 
 concentration was determined using commercial ELISA
kit (Genzyme).
 
Culture of Activated T Cells with LNPCs.
 
Proliferation of
LNPCs was inhibited by incubation with mitomycin C (50 
 
 
 
g/ml;
Sigma-Aldrich) for 30 min at 37
 
 
 
C. Previously activated T cells
(3 
 
 
 
 10
 
4
 
 cells/well) were cocultured with 2 
 
 
 
 10
 
5
 
 mitomycin C
(MMC)-treated LNPCs for 60 h in the presence or absence of
anti-PD-L1 mAb (1–111, 30 
 
 
 
g/ml) or cytotoxic T lymphocyte
antigen-4 (CTLA-4)-Ig (20 
 
 
 
g/ml; Genzyme). In some experi-
ments, previously activated T cells (3 
 
 
 
 10
 
4
 
 cells/well) were co-
cultured with MMC-treated purified Kupffer cells (4 
 
 
 
 10
 
4
 
 cells/
well), LSECs (1.6 
 
 
 
 10
 
5
 
 cells/well), or KCs 
 
  
 
LSECs (4 
 
 
 
 10
 
4
 
cells: 1.6 
 
 
 
 10
 
5
 
 cells/well) for 60 h. Proliferation was determined
by labeling of cultures for the last 12 h with BrdU. Supernatants
were collected at 48 h after initiation of cocultures and IFN-
 
 
 
was measured by ELISA as described above. In some experi-
ments, previously activated T cells were labeled with 5 
 
 
 
M CFSE
(5-(6)-carboxy-fluorescein diacetate succinimidyl diester; Molec-
ular Probes) in PBS for 8 min at room temperature and washed
three times before coculture with LNPCs.
 
In Vivo BrdU Labeling.
 
At day 0 or 7 of adenovirus infection,
mice were intraperitoneally injected with 0.5 mg of BrdU
(Sigma-Aldrich) in 0.5 ml of PBS. 1 h after BrdU injection,
 
*
 
Abbreviations used in this paper:
 
 CTLA-4, cytotoxic T lymphocyte anti-
gen-4; EC, endothelial cell; LNPC, liver nonparenchymal cell; LSEC,
liver sinusoidal endothelial cell.T
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spleen and livers were harvested for BrdU detection by flow cy-
tometry and immunohistochemistry.
 
Flow Cytometry.
 
The following reagents were used for surface
staining: anti-CD3-APC, anti-CD4-FITC, anti-CD4-PE, anti-
CD8-APC, anti-CD11b-APC, anti-CD25-PE, anti-CD31-FITC,
anti-CD44-PE, anti-CD69-PE, anti-CTLA-4-PE, anti-CD54
(ICAM-1)–FITC, anti-CD54-biotin, anti-B7–1 (CD80)–biotin,
anti-B7–2 (CD86)–biotin, and anti-CD105-FITC which were
purchased from BD Biosciences. Streptavidin (SA)-FITC and
SA-PE were purchased from DakoCytomation. Isolection B4-
FITC was purchased from Vector Laboratories. Anti-PD-1 (J43),
anti-PD-L1 (1–111), anti-PD-L2 (#122), and their conjugates
were generated in our laboratory (9, 22). 10,000 events were
analyzed on a FACSCalibur™ (Becton Dickinson) using the
CELLQuest™ software (Becton Dickinson). Kupffer cells and
LSECs were gated as CD54
 
 
 
CD11b
 
high
 
 and CD54
 
 
 
CD11b
 
low
 
cells, respectively. CD4 and CD8 T cells were gated with anti-
CD4-PE or FITC, and anti-CD8-APC, respectively.
BrdU staining was performed as described (38) with some
modifications. Briefly, freshly isolated splenocytes and IHLs were
stained for surface CD3, CD4, CD8, or CD19. The cells were
then fixed and permeabilized using FIX & PERM cell permeabi-
lization kit (Caltag). After DNA digestion, the cells were stained
with FITC-conjugated anti-BrdU (BD Biosciences) and the per-
centage of stained cells was quantified by flow cytometry.
 
Histology.
 
To examine PD-L1 localization, mice were intra-
venously injected with 100 
 
 
 
g of biotinylated anti-PD-L1 (1–
111) in 100 
 
 
 
l of PBS and organs were harvested 1 h later. 5-
 
 
 
m
of cryosections were fixed with 4% paraformaldehyde (PFA) and
stained with SA-FITC. Sections were counterstained with phal-
loidin (Molecular Probes).
For detection of ICAM-1 and PD-L1, liver cryosections (5
 
 
 
m) were fixed with 3% PFA and preincubated with normal rat
serum to block nonspecific binding. Sections were incubated
with biotinylated anti-PD-L1 (1–111) or anti–ICAM-1 (BD Bio-
sciences) for 1 h at room temperature. Biotinylated mAbs were
visualized with tyramide signal amplification (TSA) fluorescence
system (PerkinElmer).
For BrdU staining, single or double immunostaining was per-
formed by indirect immunoalkaline phosphatase method (39). For
double staining, acetone-fixed 5-
 
 
 
m liver cryosections were
stained with anti-CD4 (RM4–5; BD Biosciences) or anti-CD8
(53–6.7; BD Biosciences) using ALP substrate kit (blue; Vector
Laboratories). After further fixation with 1% glutaraldehyde in
PBS for 9 min, sections were incubated with biotinylated anti-
BrdU using a BrdU staining kit (Zymed Laboratories). Anti-BrdU
was visualized with ALP substrate kit (red; Vector Laboratories).
For histopathological studies, liver cryosections were fixed with
10% buffered formalin and stained with hematoxylin and eosin.
For X-gal staining, liver cryosections were fixed with 0.2%
glutaraldehyde and 2% formaldehyde for 10 min at room temper-
ature and then incubated in X-gal (5-bromo-4-chloro-3-indolyl-
b-D-galactopyranoside) solution for 2 h at 37
 
 
 
C. Sections were
counterstained with nuclear fast red.
 
Results
 
PD-L1 Is Expressed on Vascular Endothelium in Nonlym-
phoid Tissues.
 
Several studies showed PD-L1 expression
on human and murine ECs in culture conditions (20, 40).
To determine whether ECs express the PD-L1 protein in
vivo, we analyzed freshly isolated ECs from murine heart
by flow cytometry using an anti-PD-L1 mAb. The primary
EC isolates from heart expressed a low level of PD-L1 but
not PD-L2 (Fig. 1 a). To examine PD-L1 distribution in
the vascular system in a whole body, we intravenously in-
jected mice with biotinylated F (ab
 
 
 
)
 
2
 
 fragment of anti-PD-
L1 mAb or control IgG and examined the antibody stain-
ing in tissue sections (Fig. 1, b–g). PD-L1 was found on
the vascular endothelium in all tissues examined such as
heart, lung, kidney, salivary gland, and eye. In liver, PD-
L1 was localized in the hepatic sinusoids. Control IgG had
no staining.
 
PD-L1 Is Expressed on LNPCs.
 
We examined PD-L1
expression in the liver by immunohistochemistry using the
anti-PD-L1 mAb (Fig. 2 a). PD-L1 staining was similar to
that of ICAM-1 (CD54), which is expressed on LNPCs in-
cluding Kupffer cells and LSECs (Fig. 2 a). To confirm the
PD-L1 expression in the liver, LNPCs were isolated and
analyzed by flow cytometry (Fig. 2 b). LNPCs consisted of
CD54
 
 
 
CD11b
 
low
 
 LSECs (75–80%) and CD54
 
 
 
CD11b
 
high
 
Kupffer cells (20–25%). Kupffer cells coexpressed PD-L1
with B7–1, B7–2, and ICAM-1. The expression of PD-L1
on LSECs was weak but significant as compared with that
of B7–1 or B7–2. Neither LSECs nor Kupffer cells ex-
pressed PD-L2.
 
LNPCs Inhibit Proliferation of Activated T Cells via PD-1/
PD-L1 Signal.
 
In the microanatomical environment of
the liver, passenger T cells may be forced to contact with
LNPCs in the narrow meshwork of the hepatic sinusoids
(26). We assumed that when previously activated T cells
pass through liver sinusoids, interaction between PD-1 on
activated T cells and PD-L1 on LNPCs might induce sup-
pressive signaling in activated T cells. To examine the
function of PD-L1 on LNPCs, in vitro–activated T cells
from PD-1
 
 
 
/
 
 
 
 or WT mice were cocultured with mito-
mycin C–treated LNPCs from WT mice to measure T cell
proliferation by BrdU incorporation. When naive T cells
were stimulated with plate-bound anti-CD3 mAb, both
PD-1
 
 
 
/
 
 
 
 and WT T cells showed an activated phenotype
(CD25
 
high
 
, CD44
 
high
 
, CD69
 
high
 
) (Fig. 3). Activated CD4
 
 
 
and CD8
 
 
 
 T cells of PD-1
 
 
 
/
 
 
 
 and WT mice increased ex-
pression levels of PD-L1 and B7–2, but marginally that of
B7–1. PD-1 was strongly induced on WT CD4
 
 
 
 and
CD8
 
 
 
 T cells. The cell density in the present system ap-
peared to allow T cells to contact with each other and
provide costimulatory signal to complement TCR signal
by anti-CD3 stimulation. Proliferation of naive PD-1
 
 
 
/
 
 
 
and WT T cells activated with anti-CD3 was comparable
(Fig. 4 a).
Activated T cells were then diluted 10 folds to prevent
the T–T interactions, and cocultured with LNPCs. After
48 h of coculture, activated PD-1
 
 
 
/
 
 
 
 T cells showed
much stronger proliferative response as compared with ac-
tivated WT T cells, although activated T cells alone did
not show proliferation (Fig. 4 b). Blocking of PD-1-PD-
L1 interactions with the anti-PD-L1 mAb increased pro-
liferation of WT T cells to the level equivalent to that of
PD-1
 
 
 
/
 
 
 
 T cells, whereas control rat IgG had no effect.
Interruption of B7-CD28 interactions using the CTLA-T
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4-Ig protein decreased proliferation of PD-1
 
 
 
/
 
 
 
 T cells to
the level identical to that of WT T cells, while control hu-
man IgG had no effect. Thus, we conclude that prolifera-
tion of activated T cells is inhibited by interaction be-
tween PD-1 on T cells and PD-L1 on LNPCs, although,
in the absence of PD-1 signal, previously activated T cells
can proliferate by interaction between CD28 on T cells
and B7s on LNPCs.
To examine whether the inhibition of T cell prolifera-
tion was due to cell cycle arrest, activated T cells were la-
beled with CFSE, a reporter dye for cell division, and co-
cultured with LNPCs. PD-1
 
 
 
/
 
 
 
 T cells showed lower
intensity of CFSE as compared with WT T cells (Fig. 4 c),
suggesting that cell division of WT T cells was suppressed
by PD-1 signal.
 
The Absence of PD-1 Induces Prolonged Cytokine Produc-
tion.
 
We next investigated the role of PD-1/PD-L1 sig-
nal in cytokine production. When naive CD3 T cells
were stimulated with anti-CD3 for 2 d, IFN-
 
 
 
 production
of PD-1
 
 
 
/
 
 
 
 and WT T cells was comparable (Fig. 4 d).
Activated T cells were then diluted 10 fold and cultured
for another 2 d with or without LNPCs (Fig. 4 e). Al-
though both WT and PD-1
 
 
 
/
 
 
 
 activated T cells secreted
reduced amounts of IFN-
 
 
 
, activated PD-1
 
 
 
/
 
 
 
 T cells
showed less prominent reduction in IFN-
 
 
 
 production
than activated WT T cells (Fig. 4 e). These data suggest
that PD-1/PD-L1 signal during the activation phase
quickly down-regulates cytokine production while the
absence of PD-1 signal allows slower reduction, resulting
in prolonged IFN-
 
 
 
 production.
Figure 1. PD-L1 expression
on vascular endothelium. (a) ECs
were freshly isolated from mu-
rine heart and stained with anti-
PD-L1 or anti-PD-L2 (open
curves). The filled curves repre-
sent control IgG. (b-g) Biotin-
ylated F(ab )2 of anti-PD-L1 (b-
g1) or control IgG (b-g2) was
intravenously injected into mice
and organs were harvested 1 h
later. Sections were stained with
streptavidin-FITC (green) and
counterstained with phalloidin
(red). (b) Eye, (c) submandibular
gland, (d) lung, (e) heart, (f)
liver, (g) kidney. Ch, choroid;
CV, central vein; Gl, glomeru-
lus; Re, retina. The arrows rep-
resent vascular endothelial cells.
Original magnification,  40.T
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Subsequent coculture with LNPCs did not further in-
crease or decrease IFN-
 
 
 
 production from activated PD-
1
 
 
 
/
 
 
 
 T cells, although LNPCs had a strong proliferative
effect on activated PD-1
 
 
 
/
 
 
 
 T cells (Fig. 4, b and e).
This observation is consistent with the reports that
CD28/B7 interaction promotes Th2 but not Th1 cytok-
ine production (41, 42). Strikingly, there was no signifi-
cant reduction in IFN-  production of activated WT T
cells by coculture with LNPCs (Fig. 4 e). These results
suggest that once T cells are activated, cytokine produc-
tion cannot be blocked immediately by additional PD-1
signal.
Not Only Kupffer Cells but Also LSECs Inhibit Proliferation
of Activated T Cells. LNPCs consist of Kupffer cells and
LSECs. To examine which populations, Kupffer cells,
LSECs, or both, exert the inhibitory effect on proliferation
of activated T cells, Kupffer cells and LSECs were purified
from LNPCs by positive and negative selection, respec-
tively, using anti-CD11b magnetic beads, and cocultured
with activated PD-1 /  or WT T cells (Fig. 5). The cocul-
ture of activated PD-1 /  T cells with either Kupffer cells
or LSECs alone showed higher proliferative responses than
that of WT T cells. These results suggest that not only
Kupffer cells but also LSECs can inhibit proliferation of ac-
Figure 2. PD-L1 expression on liver nonparenchymal cells. (a) Cryosections of murine liver were stained with anti-ICAM-1 (top, green) or anti-PD-L1
(bottom, green). Nuclei were counterstained with propidium iodide (red). CV, central vein. Original magnification,  40. (b) Surface phenotype of
Kupffer cells and LSECs. LNPCs were isolated from murine livers and stained with anti-CD54 (ICAM-1)-FITC and anti-CD11b-APC, in combination
with biotinylated mAb for ICAM-1, PD-L1, B7–1, or B7–2, followed by streptavidin-PE. Kupffer cells and LSECs were gated as CD54 CD11bhigh and
CD54 CD11blow cells, respectively.T
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tivated T cells via PD-1 signal. To further confirm that the
LNPC inhibitory effect on T cell proliferation was due to
additive effects by Kupffer cells and LSECs, LNPCs were
reconstituted by combining purified Kupffer cells and
LSECs in the same ratio (1:4) as found in the original LN-
PCs, and cocultured with activated T cells. Activated PD-
1 /  T cells cocultured with the reconstituted LNPCs
showed the same level of proliferation as those cocultured
with the unfractionated LNPCs. These results suggest that
both Kupffer cells and LSECs contribute to proliferation
inhibition of activated T cells.
The Absence of PD-1 Signal Augments Proliferation of Ef-
fector T Cells in Inflamed Tissues and Antiviral Immune Re-
sponses. To investigate the function of PD-1 in liver, we
injected PD-1 /  or WT mice intravenously with recombi-
nant lacZ-expressing adenovirus (Ad-lacZ). We compared
T cell proliferation in the lymphoid organ (spleen) and in-
flamed tissue (liver) by in vivo BrdU labeling. At day 0,
there were almost no proliferating cells in the liver of both
PD-1 /  and WT mice (Fig. 6 a). At day 7, in the infected
liver of PD-1 /  mice, infiltrating lymphocytes increased
and the percentage of BrdU CD3  T cells was much
higher than that of WT mice (Fig. 6, b and c). More than
80% of BrdU  cells composed of CD4 and CD8 T cells in
the infected liver of PD-1 /  and WT mice (Fig. 6 b).
BrdU  cells in both CD4 and CD8 T cell populations in-
creased in the liver of PD-1 /  mice as compared with
WT mice (Fig. 6, b and c). In contrast, the percentage of
BrdU CD3  T cells in the spleen of PD-1 /  mice was
similar or even less than that of WT mice (Fig. 6, b and c).
These results suggest that PD-1 signal inhibits T cell prolif-
eration in inflamed tissues rather than lymphoid organs.
Consistent with the FACS analysis, immunohistochemistry
showed that BrdU  cells increased in the infected liver of
PD-1 /  mice as compared with WT mice (Fig. 7, a–d).
Double staining for BrdU and CD4 or CD8 also confirmed
that most of BrdU  cells were CD4 or CD8 T cells (Fig. 6
b, and Fig. 7, e and f).
Histologically, adenovirus-infected PD-1 /  mice showed
more severe but more transient hepatitis than WT mice
(Fig. 7, g–n). At day 7, the liver of PD-1 /  mice revealed
more extensive hepatocellular injury and mononuclear cell
infiltration in both periportal and centrilobular areas than
WT mice (Fig. 7, g and i). The liver of PD-1 /  mice con-
tained a large number of hepatocytes showing the typical
features of apoptotic cells: cell shrinkage, intensely acido-
philic cytoplasm, or even an absence of nuclei (Fig. 7 m,
arrows). However, at day 30, no evidence of hepatitis was
found in PD-1 /  mice, while the liver of WT mice still
showed mild focal cellular infiltration in sinusoids and peri-
portal areas (Fig. 7, h and j).
To examine the effect of T cell proliferation on adenovi-
rus infection, we analyzed liver sections for lacZ expression
(Fig. 7, o–r). At day 7, remarkably rapid clearance of ade-
novirus was observed in the liver of PD-1 /  mice, whereas
strong lacZ expression was sustained in the liver of WT
mice. At day 30, the virus was completely cleared from the
liver of PD-1 /  mice, while lacZ expression was still de-
tectable in the liver of WT mice. These results demonstrate
that the absence of PD-1 signal induces proliferation of ef-
fector T cells in inflamed tissues by viral infection, resulting
in rapid clearance of the virus.
Discussion
Here we report the following observations: (a) PD-L1
was widely expressed on the vascular endothelium in non-
lymphoid tissues; (b) LNPCs that constitutively expressed
PD-L1 inhibited proliferation of activated T cells express-
ing PD-1; (c) the absence of PD-1 signal induced prolifera-
Figure 3. Phenotypic analysis of activated T cells. In vitro–activated CD4  or CD8  T cells from PD-1 /  or WT mice were stained with a panel of
mAbs (thick lines) and control IgG (thin lines).T
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tion of effector T cells in the adenovirus-infected liver and
resulted in rapid clearance of the virus. These results sug-
gest that PD-L1 expressed on LNPCs may play an impor-
tant role in tolerance induction in the liver. The liver is
constantly exposed to innocuous nonpathogenic antigens
that arrive from the circulation via the hepatic artery and
from the gastrointestinal tract via the portal vein. The liver,
therefore, may have evolved unique regulatory mecha-
nisms to avoid excessive immune responses to these anti-
gens. The PD-1/PD-L1 interaction may be involved in T
cell tolerance to harmless dietary antigens and innocuous
commensal organisms.
We showed that the PD-L1 protein is abundant in the
liver. The liver has been a fascinating organ to transplanta-
tion immunologists. Allogenic liver organ transplants can
be accepted across MHC barriers (27, 43). Moreover, other
organs transplanted with the liver, which would normally
be rejected promptly, can also survive for prolonged peri-
ods (27). PD-L1 on LNPCs can transduce negative signal
to activated T cells and inhibit their proliferation, suggest-
ing that PD-L1 expression on LNPCs may be one of the
mechanisms by which the liver preferentially induces pe-
ripheral tolerance. Although LSECs can function as APCs,
our studies have not specifically addressed the regulatory
Figure 4. PD-L1 effect of LNPCs on T cell proliferation and cytokine production. (a and d) Naive T cells from PD-1 /  mice or WT mice were
stimulated with or without plate-bound anti-CD3 for 48 h. T cell proliferation was measured by BrdU incorporation (a). The culture supernatants were
harvested and IFN-  production was measured by ELISA (d). (b and e) In vitro–activated PD-1 /  or WT T cells were cocultured for 48 h with or
without mitomycin C–treated LNPCs from WT mice in the presence or absence of anti-PD-L1 (control rat IgG) or CTLA4-Ig (control human IgG). T
cell proliferation was measured by BrdU incorporation (b). The culture supernatants were harvested and IFN-  production was measured by ELISA (e).
(c) In vitro–activated PD-1 /  or WT T cells were labeled with CFSE and cocultured with LNPCs. After 48 h of incubation, T cell division was exam-
ined by FACS® analysis of CFSE intensity.T
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effect of PD-1/PD-L1 signal in antigen presentation by
LSECs. This issue remains to be evaluated.
As PD-L1 is also expressed on vascular endothelium in
other peripheral tissues, a similar regulatory system using
the PD-1/PD-L1 pathway may exist in other nonlym-
phoid tissues to maintain peripheral tolerance. ECs play
an important role in inflammatory immune responses. In
addition to their role in the recruitment of T cells, ECs
can also directly regulate T cell activation. Several studies
have shown that ECs can induce hypo-responsiveness in
T cell activation (44–46). In fact, the location of PD-L1 is
well suited for their role in peripheral tolerance. ECs re-
side at the entrance of the organ where effector T cells
migrate into the sites of inflammation. When effector T
cells enter the tissues, they first contact with ECs and the
interaction between PD-1 on activated T cells and PD-L1
on ECs can suppress T cell proliferation to limit the ex-
tent of the immune response at sites of inflammation. Our
results showed that murine ECs and LNPCs express PD-
L1 but not PD-L2 and that anti-PD-L1 mAb reversed the
LNPC inhibitory effect on T cell proliferation, suggesting
that PD-L1 may be a major negative regulator in the mu-
rine vascular system. However, PD-L2 mRNA expression
is relatively high in human tissues and the regulatory role
of PD-L2 in human may be more important (18). Al-
though PD-L1 was reported to have a costimulatory ac-
tivity (17), the PD-1/PD-L1 interaction is inhibitory and
PD-L1 may require a separate receptor for its costimula-
tory activity. The present study showed that proliferation
of activated PD-1 /  T cells was almost completely in-
hibited by the CTLA-4-Ig protein, suggesting that in our
system B7s are the major molecules which provide co-
stimulatory signal.
The regulation of immune responses can be achieved not
only at the activation phase (in secondary lymphoid organs)
but also at the effector phase (in peripheral tissues). The ac-
tivation requirement of effector T cells differs from naive T
cells: effector T cells can be activated by either TCR signal
or costimulatory signal alone. Therefore, the absence of co-
stimulatory molecules on nonlymphoid tissue cells cannot
explain the mechanism of tolerance induction at the effec-
tor phase. Our results suggest that the PD-1/PD-L1 inter-
action may play a critical role in immunoregulation at the
effector phase. In peripheral tissues, the signal between
PD-1 on effector T cells and PD-L1 on organ-resident cells
such as ECs can inhibit proliferation of effector T cells
without suppression of cytokine production. Thus, the
PD-1/PD-L1 signal allows effector T cells to accomplish
their primary functions, but blocks their proliferation in the
periphery to avoid excessive or destructive immune reac-
tions. Our results are consistent with the observation by
Harris et al. (47) that effector T cells which migrate into
nonlymphoid tissues can produce cytokines but are unable
to divide.
Our results that PD-L1 inhibits proliferation of effector
T cells but not cytokine production apparently conflict
with the observation by Mazanet et al. that PD-L1 nega-
tively regulates cytokine synthesis (40). A possible explana-
tion for these differences may be the phase of immune re-
sponses. Although they analyzed the PD-L1 function at the
activation phase in their in vitro system where naive T cells
and ECs were cocultured in the presence of PHA, we fo-
cused on the effector phase in our system where previously
activated T cells were cocultured with LNPCs. Their re-
sults are consistent with our previous reports that the rela-
tive levels of inhibitory and costimulatory signals regulate T
Figure 5. The effect of
Kupffer cells and LSECs on pro-
liferation of activated T cells. In
vitro–activated PD-1 /  or WT
T cells (3   104 cells/well) were
cocultured for 48 h with or
without mitomycin C–treated
LNPCs (before separation, 2  
105 cells/well, consisting of 20%
Kupffer cells and 80% LSECs),
purified KCs alone (4   104
cells/well), purified LSECs alone
(1.6   105 cells/well), or mix-
ture of purified Kupffer cells  
LSECs (4   104 cells: 1.6   105
cells/well). T cell proliferation was
measured by BrdU incorporation.T
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cell proliferation and cytokine production at the activation
phase (16, 18).
The immunoregulation at the effector phase is impor-
tant, especially in the case where naive self-reactive T cells
might be fortuitously activated by cross-reactivity with vi-
ral antigens. The regulation by PD-1 at the effector phase
ensures a final safeguard against such autoreactivity in pe-
ripheral tissues. On the other hand, CTLA-4 inhibitory
signal is more likely to be involved in tolerance induction
at the early activation phase and regulates the initiation of
Figure 6. BrdU  cells increased in the adnovirus-infected liver of PD-1 /  mice. PD-1 /  or WT mice (3 mice/group) were intravenously injected
with Ad-lacZ. At day 0 (a) or day 7 (b) of infection, mice were intraperitoneally injected with BrdU 1 h before sacrifice. Splenocytes and intrahepatic
lymphocytes were doubly stained for BrdU and CD19, CD3, CD4, or CD8. (c) The bars represent percentages of BrdU  cells in the CD19, CD3, CD4,
or CD8  population at day 7 after infection. The results are representative of two separate experiments.T
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Figure 7. Rapid clearance of adenovirus in
the liver of PD-1 /  mice. PD-1 /  or WT
mice were intravenously injected with Ad-
lacZ. (a–d) At day 0 or day 7 of infection,
WT (top) or PD-1 /  mice (bottom) were
intraperitoneally injected with BrdU 1 h be-
fore killing. Liver sections were stained with
anti-BrdU (red). Original magnification,  20.
(e and f) At day 7, liver sections of PD-1 / 
mice were doubly stained with anti-BrdU
(red), in combination with anti-CD4 (blue, e)
or anti-CD8 (blue, f). Original magnification,
 40. (g–r) At day 7 or 30, liver sections of
WT mice (top) or PD-1 /  mice (bottom)
were analyzed by H&E staining (g–j,  20;
k–n,  40) and X-Gal staining ( 40). The ar-
rows represent apoptotic hepatocytes.T
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autoimmune diseases (48). It is therefore possible that the
PD-1 agonists may be effective at the later phase to prevent
progression of autoimmune diseases.
Although these safeguards are critical for the avoidance
of autoimmunity, they may restrict the ability to induce
strong immune responses against infectious agents. Some
microorganisms thus escape from surveillance of the host
immune system and cause chronic infection. The fact that
the absence of PD-1 inhibitory signal can augment antiviral
immunity has significant implication for not only under-
standing of the pathogenic mechanism but also the treat-
ment of persistent infection in the liver. The temporary
blockade of the PD-1 pathway may open new therapeutic
approaches for chronic viral infections.
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